Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Johnson and Johnson
Federal Trade Commission

Generated: February 19, 2018

DrugPatentWatch Database Preview

Claims for Patent: 4,457,942

« Back to Dashboard

Summary for Patent: 4,457,942
Title: Process for waste nitrogen removal
Abstract:A method of alleviating the accumulation of waste nitrogen in human beings is disclosed, wherein phenylbutyrate, or even numbered conger thereof, is administered to a patient having such waste nitrogen accumulation. The phenylbutyrate or other compound is broken down by beta-oxidation to eventually yield phenylacetate, which is known to be useful for removing waste nitrogen from the blood stream. The present invention provides a solution to the offensive odor of phenylacetate, which is unpalatable to patients, and also can eliminate peaks and valleys of drug levels in the patient, due to the gradual formation of the desired compound phenylacetate in the patient's body.
Inventor(s): Brusilow; Saul W. (Baltimore, MD)
Application Number:06/410,018
Patent Claims: 1. A process for controlling waste nitrogen accumulation disease in a patient suffering from such waste nitrogen accumulation disease caused by an impairment in the normal synthesis of urea from ordinary waste nitrogen in the body or in the normal excretion thereof, said process comprising administering to the patient an effective amount of at least one compound of the formula: ##STR3## wherein n is 2, 4, 6 or 8, or a pharmaceutically, acceptable salt thereof, and wherein the amount of said compound administered to the patient is sufficient to produce enough phenylacetate to react with waste nitrogen to form an amino acylation product for urinary discharge of said product.

2. The process of claim 1 wherein the administration is continued until the accumulated waste nitrogen is discharged as urinary nitrogen.

3. The process of claim 1 wherein the patient is one with a urea cycle enzymopathy.

4. The process of claim 1 wherein the patient is one suffering from renal failure.

5. The process of claim 1 wherein the patient is one suffering from a hepatic failure.

6. The process of claim 1 wherein said compound is phenylbutyrate, or a salt thereof.

7. The process of claim 1 wherein the salt is the calcium salt.

8. The process of claim 1 wherein the salt is the sodium salt.

9. The process of claim 1 wherein the compound is orally administered.

10. The process of claim 1 wherein the compound is administered intravenously.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Queensland Health
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.